Treatment selection in metastatic renal cell carcinoma: expert consensus (Q37999655)

26 August 2017

Treatment selection in metastatic renal cell carcinoma: expert consensus (English)

1 reference

metastatic renal cell carcinoma

26 August 2017

1 reference

1 reference

3

1 reference

26 August 2017

1

Bernard Escudier

1 reference

26 August 2017

2

Cezary Szczylik

1 reference

26 August 2017

Martin Gore

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

10 April 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

6

1 reference

26 August 2017

327-337

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.59

26 August 2017

0 references

cites work

Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Kidney Cancer Working Group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Funding patient-reported outcomes in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sunitinib rechallenge in metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Everolimus- and temsirolimus-associated enteritis: report of three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Immunotherapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Axitinib for renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.59

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

31 March 2020

1 reference

12 December 2020

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis

1 reference

12 December 2020

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

10.1038/NRCLINONC.2012.59

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1044062746

0 references

Fatcat ID

release_ijht5bfpsndfpkeupg3qpxgjty

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ijht5bfpsndfpkeupg3qpxgjty

24 November 2022

mapped directly with Wikidata item

1 reference